XML 71 R64.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share (Detail) - shares | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 5,805,292 | 65,749,082
Stock options outstanding [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 0 | 210,000
Convertible preferred stock [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 0 | 63,603,084
Astrazeneca warrant [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 0 | 1,744,991
Deep 6 holdback liability [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 17,372 | 0
SEngine holdback liability [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 0 | 41,007
Unvested RSUs [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 5,761,861 | 0
Unvested RSAs [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 26,059 | 0
Allen & Company warrant [Member] |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |
Total potentially dilutive shares | 0 | 150,000

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tem_AstrazenecaWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tem_SharesIssuableContingentlyToDeep6KMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tem_SengineHoldbackLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tem_AllenCompanyWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |